Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL685847 | 0.82 | TSHR (0.53) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL10154044 | 0.82 | TSHR (0.53) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL685366 | 0.82 | TSHR (0.53) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL19261603 | 0.81 | TSHR (0.52) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL547287 | 0.81 | TSHR (0.52) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL24361264 | 0.80 | TSHR (0.51) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL12934522 | 0.80 | TSHR (0.51) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL685848 | 0.80 | TSHR (0.51) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL10150821 | 0.80 | TSHR (0.51) | TSHRNPSR1EPHX2CYP19A1CYP17A1 | |
| SCHEMBL26011995 | 0.80 | TSHR (0.51) | TSHRNPSR1EPHX2CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548961-B2 | Compound, resin, resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20200308095-A1 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-10-01 | — | — | US | disclosed |
| US-9599897-B2 | Salt, resin, resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9551935-B2 | Pattern forming method and resist composition | FUJIFILM CORPORATION (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160052877-A1 | SALT, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20130011785-A1 | PATTERN FORMING METHOD AND RESIST COMPOSITION | FUJIFILM CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548961-B2 | Compound, resin, resist composition and method for producing resist pattern | RER1, C1R, SMARCC2 | TSHR 2117/4885NPSR1 1585/4885EPHX2 406/4885 |
| US-20200308095-A1 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | RER1, C1R, SMARCC2 | TSHR 2117/4885NPSR1 1585/4885EPHX2 406/4885 |
| US-20160052877-A1 | SALT, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | RER1, AFF1, FRG1 | TSHR 1306/4885NPSR1 1574/4885EPHX2 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.